·
The agency posted briefing materials ahead of this week's advisory committee review of the Galleri multi-cancer blood test. The stock opened 23% higher and never looked back.
GRAIL closed Monday at $108.445, up $27.675 or 34.26%, on roughly 3.02 million shares, against a market capitalization near $4.65 billion. The shares opened at $99.78, already 23.5% above Friday's close, traded as high as $111.35 and as low as $98.66. The 52-week range is $41.50 to $118.84.
The move followed the Food and Drug Administration's release of staff briefing materials ahead of an advisory committee meeting scheduled this week to review the company's premarket approval application for Galleri, a blood test designed to detect more than 50 cancers.
The mechanics of the move
The chronology is unusually clean. The stock opened nearly a quarter higher than Friday's close, which establishes that the briefing materials were public before the 9:30 a.m. Eastern open and that the repricing happened in the premarket rather than intraday. That is the signature of a document-driven move rather than a momentum one.
Advisory committee briefing documents are a regulatory mechanism with a specific function. Agency staff publish their own assessment of a submission days before an outside expert panel convenes, so that the panel and the public can read it. Markets treat these documents as the single most informative pre-decision signal available, because they reveal how the staff who will ultimately process the application frame its strengths and weaknesses.
What is not yet established
The advisory committee has not met. Its recommendation is not binding on the agency in any case, and the agency's decision on the premarket approval application is a separate and later step.
Performance statistics for the pivotal study have circulated in commentary, including a specificity figure above 99% and a positive predictive value described as high, with sensitivity characterized as moderate. Those figures should not be treated as established until they can be read directly from the agency's own document, and the underlying tradeoff in any multi-cancer early detection test sits precisely in that sensitivity number rather than in the specificity one.
Why the economics are hard
A test screening for more than 50 cancers across an asymptomatic population faces an arithmetic problem that specificity alone does not solve. Even a very high specificity generates a meaningful absolute number of false positives when applied to a large low-prevalence population, each of which triggers a diagnostic workup with its own cost and risk. That is the question an advisory committee exists to weigh, and it is not a question a stock price can answer.
For a company with a market capitalization near $4.65 billion, approval or rejection of its lead product is close to a binary event, and Monday's 34% move reprices only the probability, not the outcome.
What to watch
The advisory committee meeting itself, this week. Then the panel's vote, the agency's eventual decision on the premarket approval application, and separately, any coverage determination, because for a screening test applied across a general population, reimbursement is as decisive as approval.